At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed May 12, 2026 at 16:05 ET
Pharvaris reported Q1 2026 EPS of €-0.59 (IFRS), a narrower loss vs €-0.85 a year ago, with cash of €247M extended by a $132M offering into 2028. The key catalysts are the CHAPTER-3 Phase 3 HAE prophylaxis data due in 3Q2026 and the NDA submission for deucrictibant IR in 1H2026.
- Q1 2026 loss per share €-0.59 vs €-0.85 YoY (IFRS basis)
- Cash and equivalents €247M as of March 31, 2026, down from €292M at Dec 31, 2025
- Closed $132.3M underwritten offering post-quarter, extending cash runway into 2028
- CHAPTER-3 Phase 3 topline data for deucrictibant XR expected in 3Q2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access